Journal: Experimental and Therapeutic Medicine

Article Title: Hydroxybutyrate promotes the recovery from cerebral infarction by activating Amp-activated protein kinase signaling

doi: 10.3892/etm.2018.6304

Figure Lengend Snippet: GHB may improve the recovery of nerve function by activating AMPK/eNOS signaling. (A) Western blot assay showed that GHB treatment resulted in the activation of AMPK and eNOS. (B) Knockdown of AMPK reduced the phosphorylation of eNOS even in the presence of GHB. n=4 biological replicates. Analysis of variance was performed. *P<0.05, ***P<0.001 as indicated. AMPK, Amp-activated protein kinase; eNOS, endothelial nitric oxide synthase; GHB, hydroxybutyrate; MCAO, middle cerebral artery occlusion.

Article Snippet: Cells were transfected with small interfering RNA (siRNA) targeting AMPK (si-AMPK), or with negative control siRNA (NC; 5′-ACUAGUCGAUCUAUGUGUGAUATT-3′) (Shanghai GenePharma Co., Ltd., Shanghai, China) using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) at the indicated concentrations, according to the manufacturer's protocol.

Techniques: Western Blot, Activation Assay, Knockdown, Phospho-proteomics

Journal: BMC Cancer

Article Title: Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer

doi: 10.1186/s12885-021-09073-z

Figure Lengend Snippet: Relative expression level of plasma circN4BP2L2 in EOC ( n = 126) compared to those in benign ovarian cysts (n = 126) ( A ) and normal controls ( n = 126) ( B ); and relative expression level of circN4BP2L2 in EOC specimens ( n = 126) compared to those in normal ovarian tissues ( n = 80) ( C )

Article Snippet: Small interference RNAs (SiRNAs) specific to circN4BP2L2 was generated by GenePharma (GenePharma Corporation, Shanghai, China) and was transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Techniques: Expressing

Journal: BMC Cancer

Article Title: Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer

doi: 10.1186/s12885-021-09073-z

Figure Lengend Snippet: Correlation between plasma circN4BP2L2 expression level and clinicopathologic parameters of EOC ( N = 126)

Article Snippet: Small interference RNAs (SiRNAs) specific to circN4BP2L2 was generated by GenePharma (GenePharma Corporation, Shanghai, China) and was transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Techniques: Expressing

Journal: BMC Cancer

Article Title: Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer

doi: 10.1186/s12885-021-09073-z

Figure Lengend Snippet: Downregulation of circN4BP2L2 promoted epithelial ovarian cancer cell migration and invasion in vitro. a Relative expression level of circN4BP2L2 in 5 different EOC cell lines (SKOV3, OVCAR3, CAOV3, HO8910 and TOV-112D) and one normal ovarian epithelial cell line (IOSE80); b After circN4BP2L2 RNA interference, the morphology of tumor cells in interference group (N1) significantly changed into spindle shape compared to that in control group (NC); c CircN4BP2L2 expression level did not affect tumor cell proliferation as indicated by CCk-8 assays in SKOV3 cells. Data are mean ± standard deviation from triplicate experiments ( P > 0.05, Student’s t-test). d Transwell migration assay was measured and the results showed that downregulation of circN4BP2L2 promoted tumor cell migration (* P < 0.05, ** P < 0.01, Student’s t-test); e Transwell invasion assay was measured and the results showed that downregulation of circN4BP2L2 promoted tumor cell invasion (* P < 0.05, ** P < 0.01, Student’s t-test); f colony formation assays were performed and the results from triplicate experiments demonstrated that circN4BP2L2 did not affect the colony formation of SKOV3 cells (* P < 0.05, ** P < 0.01, Student’s t-test); g Wound healing assay showed that downregulation of circN4BP2L2 resulted in a faster closing of scratch wounds (* P < 0.05, ** P < 0.01, Student’s t-test); h and i CircN4BP2L2 expression level did not affect tumor cell cycle or apoptosis

Article Snippet: Small interference RNAs (SiRNAs) specific to circN4BP2L2 was generated by GenePharma (GenePharma Corporation, Shanghai, China) and was transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Techniques: Migration, In Vitro, Expressing, CCK-8 Assay, Standard Deviation, Transwell Migration Assay, Transwell Invasion Assay, Wound Healing Assay

Journal: BMC Cancer

Article Title: Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer

doi: 10.1186/s12885-021-09073-z

Figure Lengend Snippet: CircN4BP2L2, CA125, and HE4 expression levels according to histology, menopause status, and FIGO stage; ROC AUC, sensitivity, specificity, and significant difference in EOC cohort vs benign ovarian cyst and normal cohorts

Article Snippet: Small interference RNAs (SiRNAs) specific to circN4BP2L2 was generated by GenePharma (GenePharma Corporation, Shanghai, China) and was transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Techniques: Expressing

Journal: BMC Cancer

Article Title: Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer

doi: 10.1186/s12885-021-09073-z

Figure Lengend Snippet: ROC AUC for circN4BP2L2, CA125, HE4 and the combination (circN4BP2L2, CA125, and HE4) in pre-menopausal EOC compared to those in pre-menopausal benign ( A ) and normal ( B ) cohorts. ROC AUC for circN4BP2L2, CA125, HE4 and the combination (circN4BP2L2, CA125, and HE4) in post-menopausal EOC compared to those in post-menopausal benign ( C ) and normal ( D ) cohorts

Article Snippet: Small interference RNAs (SiRNAs) specific to circN4BP2L2 was generated by GenePharma (GenePharma Corporation, Shanghai, China) and was transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Techniques:

Journal: BMC Cancer

Article Title: Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer

doi: 10.1186/s12885-021-09073-z

Figure Lengend Snippet: ROC AUC for circN4BP2L2, CA125 and HE4 in EOC with regard to tumor stage. It contains ROC AUC for circN4BP2L2 comparing early stage EOC with benign ( A ) and normal ( D ) cohorts; ROC AUC for CA125 comparing early stage EOC with benign ( B ) and normal ( E ) cohorts; ROC AUC for HE4 comparing early stage EOC with benign ( C ) and normal ( F ) cohorts; ROC AUC for circN4BP2L2 comparing late stage EOC with benign ( G ) and normal ( J ) cohorts; ROC AUC for CA125 comparing late stage EOC with benign ( H ) and normal ( K ) cohorts; ROC AUC for HE4 comparing late stage EOC with benign ( I ) and normal ( L ) cohorts

Article Snippet: Small interference RNAs (SiRNAs) specific to circN4BP2L2 was generated by GenePharma (GenePharma Corporation, Shanghai, China) and was transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Techniques: